All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CG-806
Therapeutic Area: Oncology Product Name: CG-806
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2020
Details:
Aptose provided a recap on CG-806 which includes, Increasing plasma exposure with increased dose levels, with sustained steady state concentration (trough level) above 2M in the latest cohort (750mg).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MCLA-145
Therapeutic Area: Oncology Product Name: MCLA-145
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
MCLA-145 is currently being evaluated in a Phase 1 open-label, multicenter dose escalation study, including a safety dose expansion phase, in patients with solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APTO-253
Therapeutic Area: Oncology Product Name: APTO-253
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Early clinical data, along with certain preclinical data, for CG-806, an oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor, and early clinical data for APTO-253, a small molecule MYC inhibitor, will be presented at the 62nd ASH Annual Meeting and Exposition.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2020
Details:
The studies highlight new information about EPI-7386. In an in vitro cellular thermal shift assay (CETSA), EPI-7386 was shown to physically interact with the both the full-length and the splice variant (AR-V7) form of the androgen receptor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Abstract titled, EPI-7386, a potent N-terminal domain androgen receptor inhibitor, with a favorable preclinical safety and superior in vitro/in vivo profile, in clinical development for prostate cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
In an in vitro VCaP model, combination treatment of EPI-7386 with enzalutamide, apalutamide or darolutamide display broader and deeper inhibition of ARassociated transcriptional activity than higher doses of each single agent alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
The Phase 1 clinical trial will evaluate the safety and tolerability of EPI-7386 while additionally characterizing the pharmacokinetic, biological and anti-tumor effects of therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
First patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer patients who failed standard of care treatments, including second generation anti-androgens.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CG-806
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
CG-806 was well-tolerated in patients treated at 150mg, 300mg and 450mg BID over multiple cycles, with no drug-related dose-limiting toxicities or serious adverse events.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): L-DOS47,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
